Core Viewpoint - Baosai Technology-B (02315) has shown a significant increase in stock price, rising over 6% following the release of its 2025 performance forecast, indicating strong growth potential in revenue and net profit [1] Financial Performance - The company expects to achieve revenue of approximately 1.369 billion to 1.389 billion yuan for the year 2025, representing a year-on-year growth of 39.61% to 41.65% [1] - The anticipated net profit attributable to shareholders is projected to be around 162 million to 182 million yuan, reflecting a substantial year-on-year increase of 384.26% to 443.88% [1] Market Position and Growth Drivers - Guolian Minsheng Securities highlighted that Baosai Technology benefits from its innovative advantages in model animals and preclinical CRO business, as well as the antibody platform supported by the "Thousand Mice and Ten Thousand Antibodies" initiative [1] - The company has established partnerships with several leading domestic and international pharmaceutical companies since 2025, and multiple pipelines have received IND approvals, which are expected to contribute to milestone payments and further revenue growth [1]
港股异动 | 百奥赛图-B(02315)午后涨超6% 25年业绩预告亮眼 对外授权打开长期增长天花板